BRENTWOOD, Tenn., Sept. 01, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), announces today it is accepting patients for medical weight loss services at IMAC Regeneration Centers. The medical weight loss service will launch in three facilities this month.
“We are excited about the launch of medical weight loss in IMAC Regeneration Centers. There was significant effort applied to develop and launch this service and we believe it can have a significant impact on our patients’ rehabilitative process while also introducing new patients to the IMAC orthopedic service line,” said Jeffrey Ervin, IMAC’s Chief Executive Officer. “Obesity is the second leading cause of back pain. Therefore, implementing the weight loss service gives us another tool to assist consumers in their battle against chronic back pain.”
The American Journal of Preventative Medicine estimates that 42% of US adults will be obese by 2030.
The medical weight loss service is administered by medical doctors and nurse practitioners that deliver injection based therapies for metabolic improvement and fat reduction. The program is customized to accommodate each person and typically ranges from $1,500 to $4,000 per year.
About IMAC Holdings, Inc.
IMAC Holdings owns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. IMAC is comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address both young and aging populations, IMAC Holdings owns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMAC’s The Back Company retail spinal health and wellness treatment centers deliver chiropractic care within Walmart locations. IMAC’s research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. For more information visit www.imacholdings.com.
###
Safe Harbor Statement
This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “believe,” “may,” “will,” “should” or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.
IMAC Press Contact:
Laura Fristoe
lfristoe@imacrc.com
